Companies Collaborate to Develop New Biopharmaceuticals for Short Bowel Syndrome

The trend of developing new biopharmaceuticals is favoring growth of the short bowel syndrome market. For instance, Huons - a manufacturer of pharmaceutical products, announced partnership with Genexine - a clinical-stage biotechnology company, to develop new biopharmaceuticals.

Companies in the short bowel syndrome market are increasing their efficacy to create treatment options in growth hormone and GLP-2 drugs. As such, growth hormone drug class segment is projected to reach a value of ~US$ 7 Mn by the end of 2027. FDA grants are enabling the development of orphan drugs, since short bowel syndrome is a rare disease.

Cross promotion is another driver that is enhancing the credibility of companies who are collaborating in the short bowel syndrome market landscape. Increasing demand for therapeutic drugs and biobetter drugs for rare diseases is another driver that is catalyzing market expansion. Manufacturers are increasing research efforts in immunotherapeutic drugs to support the biopharmaceutical industry.

short bowel syndrome market infographic

To know the scope of our report Get a Sample on Point-of-Care Short Bowel Syndrome Market  

Participation in Educational Forums Increases Awareness about Newly Launched GLP-2 Drugs

Continuous R&D has led to innovations in GLP-2 drugs. Companies in the short bowel syndrome market are increasing efforts in drug discovery for the treatment of SBS. For instance, in March 2019, global biotechnology company Theracon AG, announced that the company would reveal interim results from its ongoing phase II clinical study of apraglutide, a next-gen GLP-2 drug for treatment of SBS.

Growing adoption of GLP-2 drugs, owing to its attributes of alleviating risks of dehydration and malnutrition in patients is creating scope for incremental opportunities. Increased patient satisfaction is another driver for the growth of short bowel syndrome market.

Get a glimpse of the in-depth analysis through our Report Brochure

Manufacturers in the short bowel syndrome market are increasing production capabilities in the development of synthetic GLP-2 analog with the help of extensive preclinical characterization and optimization. They are participating in educational forums to demonstrate product developments, which in turn helps to bolster the company’s credibility credentials in the global market for short bowel syndrome. Companies are innovating in ready-to-use liquid formulations of GLP-2 analog to meet growing demands for treatment options that improve intestinal absorption.

FDA-approved Drugs Bolster Credibility Credentials of Pharmaceutical Companies

Pharmaceutical giants in the short bowel syndrome market are taking efforts to increase their portfolio of FDA-approved drugs. For instance, in May 2019, major pharmaceutical company in Asia Takeda, revealed its FDA-approved drug GATTEX® (teduglutide), to cater to the niche requirements of children.

Companies in the short bowel syndrome market are expanding their product portfolio in GLP-2, since this drug class segment is projected to reach a value of ~US$ 4.3 Bn by 2027 in the market landscape. They are addressing unmet needs of patients suffering from complex gastrointestinal conditions. Manufacturers are developing efficacious drugs that reduce dependency of patients on parenteral support. They are working closely with pediatric gastroenterologists to improve outcomes in children. Growing awareness about hormonal therapy is aiding healthcare providers to improve management of SBS in infants.

Improved Formulations of GLP-2 Drugs Enhance Outcomes in Patients

The short bowel syndrome market is largely consolidated with three market players accounting to ~50-55% of the market stake. Other challenges such as diverse effects of the GLP-2 drug glepaglutide, are presenting new hurdles for manufacturers.

Long-term parenteral support has led to several complications in patients such as intestinal failure associated liver disease (IFALD). This has led to increasing adoption of GLP-2 drug glepaglutide to improve the hepatic excretory function of the liver. As such, GLP-2 drug class segment is estimated to account for ~93% share of the short bowel syndrome market by 2027. Thus, GLP-2 drugs are anticipated to be in high demand during the forecast period.

However, changes in splanchnic perfusion leading to increased blood flow is a challenge that questions the effectiveness of glepaglutide. Hence, manufacturers in the short bowel syndrome market are developing improved formulations of glepaglutide to improve outcomes in patients. Companies are tapping into new opportunities for the production of teduglutide for patients suffering from Crohn’s disease and short bowel syndrome.

short bowel syndrome market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The short bowel syndrome market is expected to grow at a rapid CAGR of ~27% during the forecast period. Companies are developing novel long-acting GLP-2 analog, such as glepaglutide, owing to its ability to reduce fecal wet weight output and increase fluid absorption in patients.

However, risks associated with increased blood flow due to splanchnic perfusion after glepaglutide administration acts as a challenge for drug manufacturers. Hence, manufacturers should increase their efficacy in extensive preclinical characterization and glepaglutide to develop improved formulations of the drug. Manufacturers should encourage direct investments in North America, as the short bowel syndrome market in the region is projected for exponential growth in the coming years.

Short Bowel Syndrome Market: Overview

  • According to the latest report published by Transparency Market Research on the global short bowel syndrome market for the historical period 2017-2018 and forecast period from 2019 to 2027, high cost of parenteral nutrition and favorable reimbursement scenario are projected to be major drivers of the short bowel syndrome market during the forecast period
  • The short bowel syndrome market was valued at ~US$ 564 Mn in 2018 and is expected to expand at a CAGR of ~27% from 2019 to 2027
  • This report analyzes the current and future scenario of the short bowel syndrome market. The most preferred mode of treatment of short bowel syndrome in parenteral nutrition. Short bowel syndrome (SBS) is a disorder that is caused by the lack of functional intestine resulting in malabsorption. Postoperative complications due to vascular and obstructive anomalies that require extensive resection have been increasing, contributing to increase in prevalence of SBS.
  • The short bowel syndrome market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the short bowel syndrome market with respect to the segments based on drug class, and region.
  • A detailed qualitative analysis of drivers, restraints, and opportunities of the short bowel syndrome market has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles, along with business overview to understand the competitive landscape in the short bowel syndrome market.
  • This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the short bowel syndrome market 

Short Bowel Syndrome Market: Key Segments

  • In terms of drug class, the short bowel syndrome market has been categorized into glucagon-like peptide-2 (GLP-2), growth hormone, glutamine, and others. Parenteral nutrition reduces the risk of malnutrition and dehydration and gradually, the patients can be weaned off parenteral nutrition based on intestinal adaptation.
  • The primary aim of the treatment of SBS patients includes restoring fluid and electrolyte balance. Glucagon-like Peptide-2 (GLP-2) approved for the indication is administered to the patients who are on parenteral nutrition. It is an antisecretory, transit modulating, and intestinotrophic agents that enable the treatment of SBS. Intestinotrophic effects of GLP-2 are mediated by increase in the proliferation of intestinal crypt cells; increase in villous height in jejunum, duodenum, and ileum; and enterocyte proliferation in the jejunal crypt.
  • This GLP-2 aided increase in intestinal cell mass aids in mucosal growth, enhances activities of intestinal brush-border enzymes, delays the gastric transit, and increases the intestinal capacity for nutrient absorption
  • In addition, the GLP-2 analog differs from the natural GLP-2 by a single amino acid, where an alanine is replaced by a glycine. This structural difference increases the half-life of the GLP-2 analog to two hours as compared to seven minutes half-life of the natural GLP-2.
  • GLP-2 analog is also resistant to degradation by dipeptidyl peptidase-IV (DDP-IV). These features make it the most preferred mode of treatment available for SBS patients. This is likely to drive the short bowel syndrome market during the forecast period.
  • The market size and forecast for each of the segments have been provided in terms of US$ Mn from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year 

Short Bowel Syndrome Market: Regional Outlook

  • Geographically, the short bowel syndrome market has been segmented into four major regions: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Japan, and Rest of the World (India, China, Australia & New Zealand, Brazil, and Middle East)
  • The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

  • The report also profiles following mentioned major players in the short bowel syndrome market based on various attributes such as company overview, financial overview, treatment types, business strategies, and recent developments. The companies include
    • Shire plc (Takeda Pharmaceutical Company Limited)
    • Zealand Pharma A/S
    • Sancilio & Company, Inc.
    • OxThera
    • Nutrinia Ltd.
    • Ardelyx, Inc.
    • Emmaus Life Sciences, Inc.
    • GLyPharma Therapeutic, Inc. (Pfizer Inc.)
    • Merck KGaA
    • Naia Pharmaceuticals, Inc.

Short Bowel Syndrome Market - Scope of the Report

TMR’s report on the global short bowel syndrome market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the short bowel syndrome market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period. The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global short bowel syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the short bowel syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the short bowel syndrome market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the short bowel syndrome market. The next section of the short bowel syndrome report highlights the USPs, which include drivers & restraints impact analysis, value chain analysis; short bowel syndrome disease overview, short bowel syndrome epidemiology, rare diseases prevalence, overview of clinical trials for short bowel syndrome, qualitative analysis of glp-2 product, research & development cost analysis, impact analysis of clinical trials cost on orphan drugs, cost analysis of therapies using orphan drugs, approved U.S. orphan indications, 1983–2015, approved European orphan indications, 2019, pricing analysis, orphan drugs – price volume analysis, justifications for the high cost of Gattex & Teduglutide, regulations scenario assessment, flow chart guide to determine eligibility for standard orphan designation in Australia, impact analysis of regulatory scenario assessment, comparative analysis of orphan drug policies, orphan drug manufacturing companies, acquisitions timeline, and SWOT analysis.

The report analyzes the short bowel syndrome market in terms of drug class and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the short bowel syndrome market.

Key Questions Answered in Short Bowel Syndrome Market Report

  • What is the sales/revenue generated by different short bowel syndrome (SBS) across all the regions during the forecast period?
  • What are the major drivers, restraints, and opportunities in the market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?

Short Bowel Syndrome Market - Research Objectives and Research Approach

The comprehensive report on the short bowel syndrome market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the short bowel syndrome market. It is followed by market introduction, market dynamics, and an overview of the short bowel syndrome market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the short bowel syndrome market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key short bowel syndrome market manufacturers has been mapped to ascertain the size of the short bowel syndrome market in terms of value. The forecast presented here assesses the total revenue generated by dermatome devices. In order to provide an accurate forecast, we initiated by sizing up the current short bowel syndrome market with the help of the parent market.

The report also delves into the competitive landscape of the short bowel syndrome market. Key players operating in the short bowel syndrome treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the short bowel syndrome treatment market report.

Key players operating in the short bowel syndrome market include Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, and Naia Pharmaceuticals, Inc.

Short Bowel Syndrome Market – Segmentation

Drug Class

Glucagon-like Peptide-2 (GLP-2)

Growth Hormone

Glutamine

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Short Bowel Syndrome Market

Buy Now